JDRF recently posted two new opportunities.
The first is titled Overcoming Obstacles to Achieving Immune Tolerance in Type 1 Diabetes.
From JDRF:
“JDRF is soliciting letters of intent for the identification of key barriers in the way of therapeutically restoring immune tolerance in type 1 diabetes after the onset of autoimmunity (i.e., in at-risk autoantibody positive pre-diabetic, recent-onset diabetic, and established disease subjects). Such efforts are intended to support the ultimate goal of identifying targets, combination therapies, and treatment strategies for T1D. JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential.”
A letter of intent is due December 3, 2015 and applications are due March 2, 2016.
Find more information here.
The second is Discovery and Development of Immune Tolerance Delivery Systems for Antigen Specific Therapies in Type 1 Diabetes.
From JDRF:
“JDRF is soliciting letters of intent for the discovery, development and pre-clinical testing of tolerogenic delivery systems of diabetes-specific autoantigens designed to prevent and/or reverse type 1 diabetes. JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential.”
A letter of intent is due December 3, 2015 and applications are due March 2, 2016.
Find more information here.